Logo Logo Logo Logo
PL
  • Home
  • About Us
    • Our Partners
    • Work with us
  • Offer
    • HTA Reports
      • Scoping
      • Clinical analysis
      • Economic analysis
      • Budget Impact Analysis
      • Rationalisation analysis
    • Strategic consulting
    • Training courses
    • IT tools
    • Studies and registers
    • DTP
  • Database
    • Glossary
    • Bibliography
    • Publications
    • Posters
  • Contact
  • GO TO IKAR PRO
  • Home
  • About Us
    • Our Partners
    • Work with us
  • Offer
    • HTA Reports
      • Scoping
      • Clinical analysis
      • Economic analysis
      • Budget Impact Analysis
      • Rationalisation analysis
    • Strategic consulting
    • Training courses
    • IT tools
    • Studies and registers
    • DTP
  • Database
    • Glossary
    • Bibliography
    • Publications
    • Posters
  • Contact
  • GO TO IKAR PRO
Title Image
HTA Consulting / Blog
May 21, 2018 In news

Bioelectrical impedance phase angle as a prognostic indicator of survival in head-and-neck cancer

We want to invite all interested to read the article, co-authored by Magdalena Władysiuk, the vice-president of the HTA Consulting: Bioelectrical impedance phase angle as a prognostic indicator of survival in head-and-neck cancer [Full text]

Share
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
May 21, 2018 In news

AGREE II (Appraisal of Guidelines Research and Evaluation) Polish translation

Evidence-based guidelines or clinical practice guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances*. Polish Ministry of Health decided last year to introduce evidence based approach with AOTMIT (HTA Agency). The AGREE II - Appraisal

Share
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
May 14, 2018 In news

IKARpro – the number of new active substances on reimbursement in Poland

Ikarpro.pl - it is an innovative service which combines:quick access to reimbursement databases broad range of analytical tools easy to be found important information.IKAR pro is a platform allowing for quick access to up-to-date data on reimbursed drugs. The platform facilitates complex analyses on reimbursement

Share
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
May 7, 2018 In news

POL-VENT database of patients with respiratory failure

In cooperation with the Pulmonology Center in Bydgoszcz (Kujawsko-Pomorskim Centrum Pulmonologii), HTA Consulting is creating a database of patients with respiratory failure - POL-VENT, which participate in the "National program for reducing mortality due to chronic lung diseases by creating rooms for non-invasive mechanical ventilation

Share
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
April 20, 2018 In news

The availability and waiting time for reimbursed drugs with orphan status

HTA Consulting examined the availability and waiting time for reimbursed drugs with orphan status registered by EMA in Poland in 2004-2018 (18/04/2018).Currently in Poland (as of 18/04/2018), 21 innovative medicines with orphan status (out of 104) registered in EMA are reimbursed. 8 of them were

Share
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
April 13, 2018 In news, Uncategorized

The availability of orphan drugs with high unmet need

HTA Consulting assessed the availability of orphan drugs with high unmet need (non-oncological drugs, the only one with orphan status registered after 2012 by EMA). Results from 32 countries were obtained - all EU and EFTA countries were analyzed except Cyprus (as of 10/04/2018)Average number

Share
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
Copyright by HTA Consulting 2016
Prosimy o zapoznanie się z poniższymi informacjami oraz wyrażenie zgody przez kliknięcie pola „Akceptuję”. Zgodę można wycofać w dowolnym czasie. Ta strona wykorzystuje pliki cookies. Informacje zawarte w cookies wykorzystujemy m.in. w celach statystycznych i funkcjonalnych. Dalsze korzystanie z serwisu oznacza, że zgadzają się Państwo na ich zapisanie w pamięci Państwa urządzenia. Mogą Państwo samodzielnie zarządzać plikami cookies zmieniając odpowiednio ustawienia w swojej przeglądarce. W związku z powyższym zgadzam się na przetwarzanie w celach analitycznych, statystycznych i marketingowych moich danych osobowych zbieranych w ramach korzystania przeze mnie ze strony internetowej hta.pl, w tym zapisywanych w plikach cookies przez administratora danych również po rozpoczęciu obowiązywania RODO (czyli po 25 maja 2018 roku). Wyrażenie zgody jest dobrowolne. Mają Państwo prawo do jej wycofania. Wycofanie zgody nie będzie miało wpływu na zgodność z prawem przetwarzania na podstawie zgody przed jej wycofaniem.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Akceptuj Czytaj więcej
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT